97. 潰瘍性大腸炎 Ulcerative colitis Clinical trials / Disease details


臨床試験数 : 2,527 薬物数 : 1,465 - (DrugBank : 259) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

  
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05181137
(ClinicalTrials.gov)
November 5, 202110/12/2021A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative ColitisA Phase 3 Study to Evaluate the Efficacy and Long-term Safety of SHR0302 Therapy in Subjects With Moderately to Severely Active Ulcerative ColitisUlcerative ColitisDrug: SHR0302;Drug: PlaceboReistone Biopharma Company LimitedNULLRecruiting18 Years75 YearsAll368Phase 3United States;China;Georgia;Poland;Ukraine
2EUCTR2021-001940-86-PL
(EUCTR)
11/09/202109/08/2021A phase 3 Study to Evaluate the Efficacy and Safety of SHR0302 in Ulcerative Colitis.A Phase 3 Study to Evaluate the Efficacy and Long-term Safety of SHR0302 for Induction, Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis Moderately to severely active Ulcerative Colitis (UC)
MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: SHR0302 tablets
Product Code: SHR0302
INN or Proposed INN: SHR0302
Reistone Biopharma Company LimitedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
368Phase 3United States;Poland;Ukraine;Georgia;China
3NCT03675477
(ClinicalTrials.gov)
April 13, 201916/9/2018A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis.A Phase II Randomized, Placebo Controlled, Double-blind, 4 Arms Dose-ranging Study to Evaluate the Efficacy and Safety of SHR0302 Compared to Placebo in Patients With Moderate to Severe Active Ulcerative Colitis.Ulcerative ColitisDrug: SHR0302;Drug: PlacebosReistone Biopharma Company LimitedNULLCompleted18 Years75 YearsAll164Phase 2United States;China;Poland;Puerto Rico;Ukraine
4EUCTR2018-003364-31-PL
(EUCTR)
15/03/201923/01/2019A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis.A Phase II randomized, placebo controlled, double-blind, 4 arms dose-ranging study to evaluate the efficacy and safety of SHR0302 compared to placebo in patients with moderate to severe active Ulcerative Colitis. Ulcerative Colitis
MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Code: SHR0302
INN or Proposed INN: Pending
Reistone Biopharma Company LimitedNULLNot RecruitingFemale: yes
Male: yes
152Phase 2United States;Poland;Ukraine;China